Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting 2024
Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds
Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference
Akero Therapeutics CDO Sells Shares Worth Over $230,000
H.C. Wainwright Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $50
H.C. Wainwright analyst Ed Arce maintains $Akero Therapeutics(AKRO.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 44.0%
Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session